Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Arcellx Inc (ACLX – Research Report). The associated price target remains the same with $115.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Emily Bodnar’s rating is based on the promising clinical trial results for Arcellx Inc’s anito-cel therapy. The updated data from the iMMagine-1 trial indicates a high overall response rate of 97% and an improved complete response rate of 68%, suggesting a strong efficacy profile for treating relapsed/refractory multiple myeloma. The trial’s safety data is also encouraging, with no delayed neurotoxicities observed and a manageable safety profile compared to other treatments.
Furthermore, the progression-free survival and overall survival rates at six and twelve months are tracking favorably against comparable studies, reinforcing the potential of anito-cel as a leading BCMA-targeted CAR-T therapy. The absence of significant new adverse events and the differentiation in safety profile compared to existing therapies contribute to the positive outlook. These factors collectively support Emily Bodnar’s Buy rating for Arcellx Inc’s stock.
Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Femasys, and Agenus. According to TipRanks, Bodnar has an average return of -9.7% and a 26.28% success rate on recommended stocks.
In another report released today, Needham also reiterated a Buy rating on the stock with a $105.00 price target.